These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 23180522)

  • 1. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter closure of patent foramen ovale associated with atrial septal aneurysm with Amplatzer Cribriform septal occluder.
    Musto C; Cifarelli A; Pandolfi C; De Felice F; Fiorilli R; Caferri G; Violini R
    J Invasive Cardiol; 2009 Jun; 21(6):290-3. PubMed ID: 19494408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
    Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
    EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events.
    Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J
    Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
    J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
    Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gore Helex septal occluder for percutaneous closure of patent foramen ovale associated with atrial septal aneurysm: short- and mid-term clinical and echocardiographic outcomes.
    Musto C; Cifarelli A; Fiorilli R; De Felice F; Parma A; Pandolfi C; Confessore P; Bernardi L; Violini R
    J Invasive Cardiol; 2012 Oct; 24(10):510-4. PubMed ID: 23043034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
    Susuri N; Obeid S; Ulmi M; Siontis GCM; Wahl A; Windecker S; Nietlispach F; Meier B; Praz F
    EuroIntervention; 2017 Sep; 13(7):858-866. PubMed ID: 28437244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
    Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
    J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance.
    Varma C; Benson LN; Warr MR; Yeo E; Yip J; Jaigobin CS; Webb G; McLaughlin PR
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):519-25. PubMed ID: 15274165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly.
    Takafuji H; Hosokawa S; Ogura R; Hiasa Y
    Heart Vessels; 2019 Oct; 34(10):1657-1662. PubMed ID: 30868214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION).
    Puricel S; Arroyo D; Goy JJ; Praz F; Palhais N; Wahl A; Stauffer JC; Togni M; Berger A; Meier B; Cook S
    EuroIntervention; 2015 Jun; 11(2):230-7. PubMed ID: 24830681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
    Aral M; Mullen M
    Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of occluder device type on success of percutaneous closure of atrial septal defects--a medium-term follow-up study.
    Becker M; Frings D; Schröder J; Ocklenburg C; Mühler E; Hoffmann R; Franke A; Lepper W
    J Interv Cardiol; 2009 Dec; 22(6):503-10. PubMed ID: 19821880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
    Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design.
    Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Braggion G; Chinaglia M; Roncon L
    Cardiovasc Revasc Med; 2010; 11(1):29-33. PubMed ID: 20129358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.